CHU Bordeauxt

The digestive system diseases research at CHU Bordeauxt concentrates on liver cancer, evaluating novel combination therapies to improve outcomes for patients with unresectable disease.

• Unresectable hepatocellular carcinoma
• Autophagy inhibitor combined with atezolizumab‑bevacizumab
• First‑line treatment strategies
• Safety and tolerability assessments

With 10 active trials and a multidisciplinary team of 21 investigators, the site advances therapeutic options for liver malignancies.

The immune system diseases program explores targeted agents for autoimmune skin conditions and systemic lupus, aiming to reduce disease activity and improve quality of life.

• Active discoid and subacute cutaneous lupus erythematosus
• Moderate to severe hidradenitis suppurativa
• Non‑segmental vitiligo
• Immunotherapy‑naïve cutaneous squamous cell carcinoma

These studies integrate innovative JAK inhibitors and biologics, reflecting the site’s commitment to personalized immunomodulation.

In the realm of musculoskeletal diseases, CHU Bordeauxt is evaluating new regimens for bone‑derived sarcomas, seeking optimal dosing alongside standard chemotherapy.

• Metastatic Ewing sarcoma
• Regorafenib combined with VDC/IE chemotherapy
• Phase 2 dose‑finding studies
• Safety monitoring and early efficacy signals

The collaboration between oncology and orthopedic specialists supports rapid translation of findings into clinical practice.

The neoplasms portfolio spans solid tumors and melanoma, testing cutting‑edge immunotherapies and targeted agents to extend survival in high‑risk patients.

• Resected stage III/IV melanoma adjuvant therapy
• Advanced cutaneous squamous cell carcinoma
• Metastatic solid tumors across multiple histologies
• Pharmacokinetic similarity study with nivolumab

Across multiple trials, the site leverages its robust oncology infrastructure to accelerate drug development.

Focused on skin and connective tissue diseases, the center conducts trials on disorders such as lupus, vitiligo, and hidradenitis, evaluating both efficacy and safety of novel molecules.

• Deucravacitinib in active DLE/SCLE
• MK‑6194 for non‑segmental vitiligo
• Upadacitinib in adults and adolescents with hidradenitis suppurativa
• INCB099280 in advanced cutaneous squamous cell carcinoma

By integrating dermatology and immunology expertise, CHU Bordeauxt aims to deliver better therapeutic options for patients with chronic skin disease.

The virus diseases research agenda includes a randomized strategy to optimise antiviral regimens for immunocompromised patients with Covid‑19.

• OPTICOV study of nirmatrelvir/ritonavir plus remdesivir
• Extended treatment duration assessment (5 vs 10 days)
• Viral load reduction measured by RT‑PCR Ct values
• Safety monitoring in vulnerable populations

These investigations support evidence‑based management of emerging infectious threats and align with the hospital’s public health mission.